Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma

被引:1
|
作者
Wo, Yang [1 ,2 ,3 ]
Peng, Yizhou [1 ,2 ,3 ]
Wu, Zhigang [1 ,2 ,3 ]
Liu, Pengcheng [1 ,2 ,3 ]
Shang, Yan [1 ,2 ,3 ]
Shen, Xuxia [4 ,5 ,7 ]
Sun, Yihua [1 ,2 ,3 ,6 ]
机构
[1] Fudan Univ Shanghai Canc Ctr, State Key Lab Genet Engn, Shanghai, Peoples R China
[2] Fudan Univ, Dept Thorac Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Inst Thorac Oncol, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[5] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Fudan Univ, Dept Thorac Surg, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China
[7] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 11期
基金
中国国家自然科学基金;
关键词
nomogram; prognostic factor; radiotherapy; SEER; STAGING PROJECT PROPOSALS; FORTHCOMING 8TH EDITION; MODULATED RADIATION-THERAPY; EXTRAPLEURAL PNEUMONECTOMY; IASLC MESOTHELIOMA; TNM CLASSIFICATION; HEMITHORACIC RADIOTHERAPY; PROGNOSTIC-FACTORS; DESCRIPTORS; PATTERNS;
D O I
10.1002/cam4.5955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The role of postoperative radiotherapy (PORT) in malignant pleural mesothelioma (MPM) remains controversial and the eighth edition TNM staging scheme for MPM has not been fully verified. We aimed to develop an individualized prediction model for identifying optimal candidates for PORT among MPM patients who received surgery plus chemotherapy and externally validate the performance of the new TNM staging scheme.Materials and Methods: Detailed characteristics of MPM patients during 2004-2015 were retrieved from SEER registries. Propensity score matching (PSM) was conducted to reduce disparities of baseline characteristics (age, sex, histologic type, stage, and type of surgery) between the PORT group and no-PORT group. A novel nomogram was constructed based on independent prognosticators identified by multivariate Cox regression model. The discriminatory performance and degree of calibration were evaluated. We stratified patients into different risk groups according to nomogram total scores and estimated the survival benefit of PORT in different subgroups in order to identify the optimal candidates.Results: We identified 596 MPM patients, among which 190 patients (31.9%) received PORT. PORT conferred significant survival benefit in the unmatched population, while there was no significant survival difference favoring PORT in the matched population. The C-index of the new TNM staging scheme was closed to 0.5, which represented a poor discriminatory ability. A novel nomogram was constructed based on clinicopathological factors, including age, sex, histology, and N stage. We stratified patients into three risk groups. Subgroup analyses indicated that PORT was beneficial for high-risk group (p = 0.003) rather than low-risk group (p = 0.965) and intermediate-risk group (p = 0.661).Conclusion: We established a novel predictive model, which could make individualized prediction of survival benefit of PORT for MPM and could compensate for weakness in TNM staging system.
引用
收藏
页码:12452 / 12461
页数:10
相关论文
共 50 条
  • [31] Surgery and Survival of Patients with Diagnosis of Malignant Pleural Mesothelioma In Response
    Bille, Andrea
    Porcu, Luca
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : E93 - E94
  • [32] Effects of treatment regimens on survival in patients with malignant pleural mesothelioma
    Abakay, A.
    Abakay, O.
    Tanrikulu, A. C.
    Sezgi, C.
    Sen, H.
    Kaya, H.
    Kucukoner, M.
    Kaplan, M. A.
    Celik, Y.
    Senyigit, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2013, 17 (01) : 19 - 24
  • [33] Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma
    Rosenzweig, Kenneth E.
    Zauderer, Marjorie G.
    Laser, Benjamin
    Krug, Lee M.
    Yorke, Ellen
    Sima, Camelia S.
    Rimner, Andreas
    Flores, Raja
    Rusch, Valerie
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04): : 1278 - 1283
  • [34] Pleural Mesothelioma: Nintedanib without Survival Benefit
    Simon, Annika
    PNEUMOLOGIE, 2019, 73 (10):
  • [35] Malignant pleural mesothelioma (MM): Outcome following radiotherapy in 300 patients
    deGraafStrukowska, L
    Senan, S
    vanPutten, WLJ
    vanderZee, J
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 433 - 433
  • [36] Survival from malignant pleural mesothelioma is predicted by FDG PET
    Klabatsa, Astero
    Chicklore, Sugama
    Barrington, Sally
    Lang-Lazdunski, Loic
    Cook, Gary
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [37] Malignant Pleural Mesothelioma in Patients Who Previously Received Radiotherapy for Their First Malignant Tumor
    Sekine, Ikuo
    Yamamoto, Yoshiyuki
    Suzuki, Toshio
    Suzuki, Hideo
    INTERNAL MEDICINE, 2021, 60 (05) : 663 - 665
  • [38] Intensity Modulated Radiotherapy of Malignant Pleural Mesothelioma - Treatment Toxicity, Tumor Control, and Survival
    Thieke, C.
    Roeder, F.
    Timke, C.
    Zwicker, F.
    Askoxylakis, V.
    Dinkel, J.
    Muenter, M. W.
    Hoffmann, H.
    Debus, J.
    Huber, P. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S502 - S503
  • [39] Multivariate Model for Predicting Overall Survival in Malignant Pleural Mesothelioma After Adjuvant Radiotherapy
    Li, V. R.
    Wang, Z.
    Yu, V. Y.
    Dams, R. V.
    Philipson, R.
    Lee, P.
    Kishan, A. U.
    Lee, A.
    Qi, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E131 - E132
  • [40] Improvement in survival rates for malignant pleural mesothelioma
    Habacher, W
    MEDIZINISCHE KLINIK, 2003, 98 (01) : 59 - 59